Good question ED as I was/am puzzled by this as well. It was later suggested that as an open label trial it would not have the power of the double blinded trial but one would still think historic results in frontline would do great things for Bavi and the share price. I think another important question is around the degree of separation between the Bavi and control arms as the independent reads of PFS in this trial we very close. Even historic MOS numbers in the Bavi arm could be nullified here as FTM noted all that matters is the difference between the two arms in the same trial.
News 
Market Data 
Discover 
AI
